Fundraising FoxAlphina Therapeutics
New Haven, US · Founded 2021 · Delaware corporation · 4 known investors
Find your way into Alphina Therapeutics
Sign up to see every warm intro you have to Alphina Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alphina Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.
Founders & leadership
NJ
Nicholas J GalliExecutive
SC
Stanley ChoyChief Financial OfficerStanley Choy is an executive officer at Alphina Therapeutics with over 25 years of healthcare and biotechnology experience, including roles as Chief Financial Officer at Edwards, Angell, Palmer & Dodge LLP, Financial Controller at Sherman & Sterling LLP, and senior finance positions at Pfizer Inc.
RB
Board
CC
AA
KR
Investors · 4
Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Colleen Cuffaro · board
How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17M disclosed across 2 rounds · 2021–2026
▶$153.7KraisedMar 2026 · 3 investors · BiotechnologyRule 506(b)
▶$153.7KraisedMar 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barbara FoxExecutive Officer, Director
- Colleen CuffaroDirector
- Nicholas J GalliExecutive Officer, Director
- Kevin RakinDirector
- Matthew CohenDirector
- Ranjit BindraDirector
- Offering amount
- $10M
- Amount sold
- $153.7K
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.9MraisedSep 2021 · 19 investors · BiotechnologyRule 506(b)
▶$16.9MraisedSep 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colleen CuffaroExecutive Officer, Director
- Anurag AgarwalDirector
- Ranjit BindraExecutive Officer, Director
- Kevin L. RakinExecutive Officer, Director
- Stanley ChoyExecutive Officer
- Offering amount
- $40M
- Amount sold
- $16.9M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Alphina Therapeutics went on to found or lead other companies.
Related companies · 4
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Intellia TherapeuticsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Jnana TherapeuticsJnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
Companies working in the same space as Alphina Therapeutics.
In the news
Frequently asked questions
- What does Alphina Therapeutics do?
- Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.
- Who are Alphina Therapeutics's investors?
- Alphina Therapeutics's investors include Canaan Partners, Connecticut Innovations, HighCape Capital, OUP (Osage University Partners).
- How much funding has Alphina Therapeutics raised?
- Alphina Therapeutics has disclosed $17M raised across 2 rounds.
- Where is Alphina Therapeutics headquartered?
- Alphina Therapeutics is headquartered in New Haven, US.